Science 37 Holdings, Inc. Forecasted to Earn FY2025 Earnings of $0.15 Per Share (NASDAQ:SNCE)

Science 37 Holdings, Inc. (NASDAQ:SNCEGet Rating) – Equities researchers at William Blair boosted their FY2025 earnings per share estimates for Science 37 in a research report issued on Monday, May 9th. William Blair analyst J. Kreger now forecasts that the company will earn $0.15 per share for the year, up from their prior estimate of $0.13. William Blair also issued estimates for Science 37’s FY2026 earnings at $0.31 EPS.

Separately, Robert W. Baird reissued a “buy” rating and set a $12.00 price target on shares of Science 37 in a research report on Friday, April 8th.

SNCE opened at $3.09 on Wednesday. The business’s 50-day moving average price is $4.82 and its two-hundred day moving average price is $8.34. Science 37 has a 1 year low of $2.82 and a 1 year high of $15.10.

Science 37 (NASDAQ:SNCEGet Rating) last issued its quarterly earnings results on Tuesday, March 22nd. The company reported ($0.29) EPS for the quarter. The firm had revenue of $20.38 million for the quarter, compared to the consensus estimate of $15.02 million.

Hedge funds have recently added to or reduced their stakes in the business. Qube Research & Technologies Ltd lifted its stake in shares of Science 37 by 90.4% during the 1st quarter. Qube Research & Technologies Ltd now owns 324,564 shares of the company’s stock worth $1,736,000 after buying an additional 154,124 shares during the last quarter. Cannon Global Investment Management LLC acquired a new stake in shares of Science 37 during the 1st quarter worth $371,000. Sciencast Management LP bought a new position in Science 37 in the 1st quarter valued at about $205,000. Walleye Capital LLC bought a new stake in Science 37 during the fourth quarter worth $164,000. Finally, BlackRock Inc. bought a new position in shares of Science 37 in the fourth quarter worth about $8,310,000. 46.12% of the stock is owned by hedge funds and other institutional investors.

Science 37 Company Profile (Get Rating)

Science 37 Holdings, Inc engages in the development of a technology platform to enable agile clinical trials and specialized networks to orchestrate trial execution. The company develops agile clinical trial operating system that enables modern and digital approaches to clinical research by bringing together all parties, including the patient and trial investigators, nurses, coordinators, as well as sponsors?to power workflows, centralize evidence generation, and harmonize data.

Further Reading

Receive News & Ratings for Science 37 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Science 37 and related companies with's FREE daily email newsletter.